| Literature DB >> 31249059 |
Xiangyu Liu1, Ali Masoudi2, Alem W Kahsai2, Li-Yin Huang2, Biswaranjan Pani2, Dean P Staus2, Paul J Shim2, Kunio Hirata3,4, Rishabh K Simhal2, Allison M Schwalb2, Paula K Rambarat2, Seungkirl Ahn2, Robert J Lefkowitz5,6,7, Brian Kobilka8,9.
Abstract
Drugs targeting the orthosteric, primary binding site of G protein-coupled receptors are the most common therapeutics. Allosteric binding sites, elsewhere on the receptors, are less well-defined, and so less exploited clinically. We report the crystal structure of the prototypic β2-adrenergic receptor in complex with an orthosteric agonist and compound-6FA, a positive allosteric modulator of this receptor. It binds on the receptor's inner surface in a pocket created by intracellular loop 2 and transmembrane segments 3 and 4, stabilizing the loop in an α-helical conformation required to engage the G protein. Structural comparison explains the selectivity of the compound for β2- over the β1-adrenergic receptor. Diversity in location, mechanism, and selectivity of allosteric ligands provides potential to expand the range of receptor drugs.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31249059 PMCID: PMC6705129 DOI: 10.1126/science.aaw8981
Source DB: PubMed Journal: Science ISSN: 0036-8075 Impact factor: 47.728